| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5693804 | European Urology | 2017 | 10 Pages |
Abstract
Androgen deprivation therapy-enzalutamide treatment may not be the best choice for prostate cancer patients who have higher expression of the Malat1/androgen receptor splicing variant 7 axis, and new therapies using Malat1-short interfering RNA or ASC-J9® may be developed in the future to better suppress enzalutamide-resistant prostate cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Ronghao Wang, Yin Sun, Lei Li, Yuanjie Niu, Wanying Lin, Changyi Lin, Emmanuel S. Antonarakis, Jun Luo, Shuyuan Yeh, Chawnshang Chang,